Bionano Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>BG</div>
BNGO -- USA Stock  

USD 11.04  1.17  9.58%

As many millenniums are trying to avoid healthcare space, it makes sense to outline Bionano Genomics a little further and try to understand its current market patterns. For some short-term oriented investors Bionano Genomics may be the right move right now, Let's take a closer look. The returns on the market and returns on Bionano Genomics appear somewhat sensitive to each other for the last few months. Conflicting basic indicators of the company may also entail signs of long-standing losses for Bionano institutional investors. The upcoming quarterly report is expected on the 9th of March 2021. The stock is still going through an active upward rally.
Published over three weeks ago
View all stories for Bionano Genomics | View All Stories
Will Bionano Genomics (NASDAQ:BNGO) price continue to rise in February?
Bionano Genomics's average rating is Buy from 4 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Bionano Genomics market sentiment investors' perception of the future value of Bionano. Let us look at a few aspects of Bionano technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Bionano Genomics. In general, we focus on analyzing Bionano Genomics stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bionano Genomics's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Bionano Genomics's intrinsic value. In addition to deriving basic predictive indicators for Bionano Genomics, we also check how macroeconomic factors affect Bionano Genomics price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Bionano Genomics' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Bionano Genomics in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Bionano Genomics. Your research has to be compared to or analyzed against Bionano Genomics' peers to derive any actionable benefits. When done correctly, Bionano Genomics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Bionano Genomics.

How does Bionano Stands against Peers?

Analyzing Bionano Genomics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Bionano Genomics across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Bionano Genomics Competition Details

How Bionano utilizes its cash?

To perform a cash flow analysis of Bionano Genomics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Bionano Genomics is receiving and how much cash it distributes out in a given period. The Bionano Genomics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Bionano Genomics Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (28.67 Million)

Acquisition by Stewart Christopher P of 8000 shares of Bionano Genomics subject to Rule 16b-3

Legal trades by Bionano Genomics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Bionano insider trading alert for grant of common stock by Stewart Christopher P, Chief Financial Officer, on 25th of January 2021. This event was filed by Bionano Genomics Inc with SEC on 2021-01-25. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at Bionano Genomics Standard Deviation

Bionano Genomics has current Standard Deviation of 12.59. The Standard Deviation is a measure of how spread out the prices or returns of an asset are on average. It is the most widely used risk indicator in the field of investing and finance. Standard Deviation is commonly used to measure confidence in statistical conclusions regarding certain equity instruments or portfolios of equities.

Standard deviation is applied to the annual rate of return of an investment to measure the investment's volatility. Standard deviation is also known as historical volatility and is used by investors as a gauge for the amount of expected market volatility. A large standard deviation usually indicates that the data points are far from the mean and a small standard deviation indicates that they are clustered closely around the mean.

Standard Deviation 
=  
SQRT(V) 
 = 
12.59
SQRT = Square root notation
V =   Variance of Bionano Genomics returns
Let's now compare Bionano Genomics Standard Deviation to its closest peers:
BNGO
A
CO
GH
LH
BNGO12.591206442782859
A1.42
CO2.54
GH2.78
LH1.68

Will Bionano Genomics growth be feasible after the rise?

Market Risk Adjusted Performance just dropped to -9.5, may entail upcoming price decrease. Bionano Genomics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Bionano Genomics independently to ensure intended market timing strategies are aligned with expectations about Bionano Genomics volatility.

Whereas many of the other players under the diagnostics & research industry are still a bit expensive, Bionano Genomics may offer a potential longer-term growth to institutional investors. With a less-than optimistic outlook for your 30 days horizon, it may be a good time to exit some or all of your Bionano Genomics holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Bionano Genomics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Bionano Genomics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com